RUNX1 and acute myeloid leukemia: In AML, by treatment with a BET protein inhibitor or degrader (BET–proteolysis targeting chimera), RUNX1 and its targets are regressed, inducing apoptosis and promoting survival of mice engrafted with AML expressing mutant RUNX1 [159].